JP2012508791A - アテローム性動脈硬化症の治療のための循環酸化低密度リポタンパク質‐ベータ‐2‐糖タンパク質1複合体を減少させる方法 - Google Patents
アテローム性動脈硬化症の治療のための循環酸化低密度リポタンパク質‐ベータ‐2‐糖タンパク質1複合体を減少させる方法 Download PDFInfo
- Publication number
- JP2012508791A JP2012508791A JP2011543839A JP2011543839A JP2012508791A JP 2012508791 A JP2012508791 A JP 2012508791A JP 2011543839 A JP2011543839 A JP 2011543839A JP 2011543839 A JP2011543839 A JP 2011543839A JP 2012508791 A JP2012508791 A JP 2012508791A
- Authority
- JP
- Japan
- Prior art keywords
- oil
- fatty acid
- edible
- oxldl
- circulating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Botany (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
本願は、2008年11月14日出願の米国仮特許出願第61/114,823号の利益を主張するものである。
本発明の態様は、アテローム性動脈硬化症の予防および治療のための、循環酸化低密度リポタンパク質‐ベータ‐2‐糖タンパク質1複合体を減少させる、天然の多価不飽和脂肪酸(PUFA)含有料理油組成物に関する。
ミエロペルオキシダーゼ(MPO)は、好中球、単球、およびマクロファージで発現されるヘムペルオキシダーゼ‐シクロオキシゲナーゼ酵素である。MPOは、強力な抗菌性物質である次亜塩素酸などの殺菌性の反応性酸化体を形成することにより、自然免疫防御系に関与する。しかし、次亜塩素酸はまた、核酸塩基と反応することも報告されており、その結果、炎症過程におけるDNA損傷に対するマーカーであり、ヒトアテローム性動脈硬化症組織中に豊富に存在する5‐クロロウラシルが形成される。
グループA − 3ヶ月の期間にわたり、通常の料理用途に用いられる7.5重量/重量%の藻油を含有する料理油を3×500ml。
グループB − 3ヶ月の期間にわたり、通常の料理用途に用いられる標準的な落花生油を3×500ml。
グループC − 3ヶ月の期間にわたり、通常の料理用途に用いられる標準的なヒマワリ油を3×500ml。
7.5重量/重量%の藻油を含有する料理油を用いた患者対ヒマワリおよび落花生料理油を用いた患者である第一の試験では、血漿を採取して循環oxLDL‐β2GPI複合体を測定し、本明細書で述べる結果を得た。
y = 3.6382x2 + 89.54x − 0.1227
R2 = 0.9999
グループBには、250mg/kg体重の藻油を与えた。
グループAにおける循環oxLDL減少の平均=95%の信頼レベルにおいて−12.02%+/−0.71
グループBにおける循環oxLDL減少の平均=95%の信頼レベルにおいて−4.64%+/−0.40
1日あたり、混合PUFAを含有する2×500mgの魚油カプセルを処方された対象における酸化LDL‐ベータ‐2‐糖タンパク質の減少に関する本発明者らの研究の過程において、本発明者らはまた、そのようなoxLDLの減少が起こり得るメカニズムの1つ、すなわち循環ミエロペルオキシダーゼに応じた減少についても調べた。
a)容器に食用の料理油を投入すること;
b)魚類油および藻油から成る群より選択される少なくとも1つの油をこの容器に添加すること;および、
c)この油を混合されるまで攪拌すること、
を含むプロセス、をさらに含む。
Claims (9)
- アテローム性動脈硬化症の予防および治療の手段としての、ヒト血清中の循環oxLDL‐ベータ‐2‐糖タンパク質1複合体および循環ミエロペルオキシダーゼを減少させるための方法であって;
1〜99重量%の多価不飽和脂肪酸(PUFA)を含有する食事用油組成物(dietary oil composition)の効果量をヒトに投与することを含む、方法。 - 前記食事用油組成物は、食用の料理油をさらに含み;
前記組成物は:
(i)飽和脂肪酸(SFA)15〜55重量%;
(ii)一不飽和脂肪酸(MUFA)40〜80重量%;および、
(iii)多価不飽和脂肪酸(PUFA)5〜45重量%、
の脂肪酸分布を有する、請求項1に記載の方法。 - 前記食事用油組成物は、カプセルを介して投与され、前記カプセルは:
(i)飽和脂肪酸(SFA)5〜10重量%;
(ii)一不飽和脂肪酸(MUFA)5〜10重量%;および、
(iii)多価不飽和脂肪酸(PUFA)20〜90重量%、
の脂肪酸分布を有する食事用油組成物を含有する、請求項1に記載の方法。 - 好ましい前記多価不飽和脂肪酸は、それぞれ0.5〜1、0.1〜1、0.1〜0.5の比率でのドコサへキサエン酸(DHA)、エイコサペンタエン酸(EPA)、およびドコサペンタエン酸(DPA)の混合物である、請求項1に記載の方法。
- 前記PUFA画分は、魚類油(marine oil)および藻油から成る群より選択される少なくとも1つの油を含み、前記魚類油は、EPA、DHA、DPA、および天然の抗酸化剤の混合物を含む、請求項1に記載の方法。
- 前記食用の料理油は植物油を含む、請求項2に記載の方法。
- 前記食用の料理油は、落花生油、糠油、大豆油、トウモロコシ油、ゴマ油、カノーラ油、サフラワー油、オリーブ油、およびピーナッツ油から成る群より選択される油を含む、請求項2に記載の方法。
- 前記食用の料理油は、ビタミンA、ビタミンD、ビタミンE、または抗酸化植物抽出物の少なくとも1つをさらに含む、請求項2に記載の方法。
- 請求項2に記載の食事用油組成物を製造するためのプロセスであって:
a)容器に食用の料理油を投入すること;
b)魚類油および藻油から成る群より選択される少なくとも1つの油を前記容器に添加すること;および、
c)前記油を混合されるまで攪拌すること、
を含むプロセス。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11482308P | 2008-11-14 | 2008-11-14 | |
US61/114,823 | 2008-11-14 | ||
PCT/IB2009/007669 WO2010055419A2 (en) | 2008-11-14 | 2009-11-10 | A method of lowering circulating oxidized low density lipoprotein-beta-2-glycoprotein 1 complex for treatment of atherosclerosclerosis |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015002682A Division JP2015091855A (ja) | 2008-11-14 | 2015-01-08 | アテローム性動脈硬化症の治療のための循環酸化低密度リポタンパク質‐ベータ‐2‐糖タンパク質1複合体を減少させる方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2012508791A true JP2012508791A (ja) | 2012-04-12 |
JP2012508791A5 JP2012508791A5 (ja) | 2012-12-27 |
Family
ID=42170470
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011543839A Pending JP2012508791A (ja) | 2008-11-14 | 2009-11-10 | アテローム性動脈硬化症の治療のための循環酸化低密度リポタンパク質‐ベータ‐2‐糖タンパク質1複合体を減少させる方法 |
JP2015002682A Pending JP2015091855A (ja) | 2008-11-14 | 2015-01-08 | アテローム性動脈硬化症の治療のための循環酸化低密度リポタンパク質‐ベータ‐2‐糖タンパク質1複合体を減少させる方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015002682A Pending JP2015091855A (ja) | 2008-11-14 | 2015-01-08 | アテローム性動脈硬化症の治療のための循環酸化低密度リポタンパク質‐ベータ‐2‐糖タンパク質1複合体を減少させる方法 |
Country Status (11)
Country | Link |
---|---|
US (1) | US9446013B2 (ja) |
EP (1) | EP2355812B1 (ja) |
JP (2) | JP2012508791A (ja) |
KR (1) | KR20110098909A (ja) |
CN (1) | CN102202661A (ja) |
AU (1) | AU2009315314B2 (ja) |
BR (1) | BRPI0915247A2 (ja) |
CA (1) | CA2743434C (ja) |
DK (1) | DK2355812T3 (ja) |
MX (1) | MX2011005077A (ja) |
WO (1) | WO2010055419A2 (ja) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8952000B2 (en) | 2011-02-16 | 2015-02-10 | Pivotal Therapeutics Inc. | Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events |
US9119826B2 (en) | 2011-02-16 | 2015-09-01 | Pivotal Therapeutics, Inc. | Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels |
US8715648B2 (en) | 2011-02-16 | 2014-05-06 | Pivotal Therapeutics Inc. | Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics |
US8951514B2 (en) | 2011-02-16 | 2015-02-10 | Pivotal Therapeutics Inc. | Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels |
NO344004B1 (en) * | 2017-06-23 | 2019-08-12 | Olivita As | Combination of oils |
WO2021080951A1 (en) * | 2019-10-21 | 2021-04-29 | President And Fellows Of Harvard College | Compositions and methods for detection of oxidizable analytes |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2238476A (en) * | 1989-11-04 | 1991-06-05 | K T Lalvani | Therapeutic aquatic animal and garlic products |
JPH08175988A (ja) * | 1994-08-25 | 1996-07-09 | Prospa Bv | 多価不飽和脂肪酸、それらのエステルまたは塩を抗酸化性ビタミンまたはプロビタミンと含んでなる薬剤調製物 |
JP2001346517A (ja) * | 2000-06-02 | 2001-12-18 | K-Tac Planners Co Ltd | 食用油脂。 |
JP2008520221A (ja) * | 2004-11-16 | 2008-06-19 | ウニベルシダッド アウトノマ デ マドリッド | 強化食品の調製のための天然生物活性成分の油状混合物 |
WO2008088415A1 (en) * | 2006-10-18 | 2008-07-24 | Reliant Pharmaceuticals, Inc. | Omega-3 fatty acids for reduction of lp-pla2 levels |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8524275D0 (en) * | 1985-10-02 | 1985-11-06 | Efamol Ltd | Pharmaceutical & dietary compositions |
US4681893A (en) | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
US5631365A (en) | 1993-09-21 | 1997-05-20 | Schering Corporation | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
US5578334A (en) * | 1995-04-07 | 1996-11-26 | Brandeis University | Increasing the HDL level and the HDL/LDL ratio in human serum with fat blends |
IT1277953B1 (it) * | 1995-12-21 | 1997-11-12 | Sigma Tau Ind Farmaceuti | Composizione farmaceutica contenente l-carnitina o una alcanoil l- carnitina e un acido poliinsaturo della serie 3-omega utile per |
DE19855426A1 (de) * | 1998-12-02 | 2000-06-08 | Wolfgang Langhoff | Mittel zur Therapie und Prophylaxe von rheumatisch-arthritischen Erkrankungen und zur Prophylaxe von cardiovaskulären Erkrankungen |
DE20105126U1 (de) * | 2001-03-23 | 2002-01-31 | Bartz Volker | Fischöl zur oralen Einnahme |
GB0210212D0 (en) * | 2002-05-03 | 2002-06-12 | Univ Southampton | Effects of dietary N-3 and N-6 pufa intake on atheromatous plaque stability |
CN1665496B (zh) * | 2002-05-03 | 2010-05-05 | 派普生物保健品公司 | Epa和dha在制备二级预防神经性疾患的药物中的用途 |
PL1876906T3 (pl) * | 2005-04-29 | 2010-07-30 | Vinorica S L | Suplement diety lub żywność funkcjonalna zawierające mieszaninę olejów |
EP1964554A1 (en) * | 2005-11-30 | 2008-09-03 | Katry Inversiones, S.L. | Lipid mixture and use thereof for the preparation of a product that is intended for enteral or oral administration |
PT1800675E (pt) * | 2005-12-23 | 2011-08-30 | Nutricia Nv | COMPOSIÇÃO CONTENDO ÁCIDOS GORDOS POLI-INSATURADOS, PROTEÍNAS E MANGANjS E/OU MOLIBDÉNIO PARA O MELHORAMENTO DA COMPOSIÇÃO DA MEMBRANA |
JP5099808B2 (ja) * | 2006-05-29 | 2012-12-19 | 独立行政法人農業・食品産業技術総合研究機構 | 脂質代謝改善用組成物 |
WO2008085019A1 (en) * | 2007-01-11 | 2008-07-17 | Carotino Sdn. Bhd. | A method for lowering risk of cardiovascular diseases |
-
2009
- 2009-11-10 BR BRPI0915247A patent/BRPI0915247A2/pt not_active Application Discontinuation
- 2009-11-10 CA CA2743434A patent/CA2743434C/en active Active
- 2009-11-10 KR KR1020117013499A patent/KR20110098909A/ko not_active Application Discontinuation
- 2009-11-10 CN CN2009801442637A patent/CN102202661A/zh active Pending
- 2009-11-10 US US13/125,806 patent/US9446013B2/en active Active - Reinstated
- 2009-11-10 EP EP09825826.2A patent/EP2355812B1/en active Active
- 2009-11-10 JP JP2011543839A patent/JP2012508791A/ja active Pending
- 2009-11-10 AU AU2009315314A patent/AU2009315314B2/en active Active
- 2009-11-10 WO PCT/IB2009/007669 patent/WO2010055419A2/en active Application Filing
- 2009-11-10 DK DK09825826.2T patent/DK2355812T3/da active
- 2009-11-10 MX MX2011005077A patent/MX2011005077A/es active IP Right Grant
-
2015
- 2015-01-08 JP JP2015002682A patent/JP2015091855A/ja active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2238476A (en) * | 1989-11-04 | 1991-06-05 | K T Lalvani | Therapeutic aquatic animal and garlic products |
JPH08175988A (ja) * | 1994-08-25 | 1996-07-09 | Prospa Bv | 多価不飽和脂肪酸、それらのエステルまたは塩を抗酸化性ビタミンまたはプロビタミンと含んでなる薬剤調製物 |
JP2001346517A (ja) * | 2000-06-02 | 2001-12-18 | K-Tac Planners Co Ltd | 食用油脂。 |
JP2008520221A (ja) * | 2004-11-16 | 2008-06-19 | ウニベルシダッド アウトノマ デ マドリッド | 強化食品の調製のための天然生物活性成分の油状混合物 |
WO2008088415A1 (en) * | 2006-10-18 | 2008-07-24 | Reliant Pharmaceuticals, Inc. | Omega-3 fatty acids for reduction of lp-pla2 levels |
Non-Patent Citations (4)
Title |
---|
JPN6014002441; Atherosclerosis, 2004, 176(1), p.145-9 * |
JPN6014002443; Life Sci, 1997, 61(19), PL269-74 * |
JPN7014000240; Blood, 1981, 58(5), p.880-5 * |
JPN7014000241; DATABASE CAPLUS AN 1983:611495 * |
Also Published As
Publication number | Publication date |
---|---|
CA2743434C (en) | 2015-04-21 |
MX2011005077A (es) | 2011-05-25 |
WO2010055419A2 (en) | 2010-05-20 |
WO2010055419A3 (en) | 2010-09-10 |
AU2009315314A1 (en) | 2010-05-20 |
KR20110098909A (ko) | 2011-09-02 |
US20110207821A1 (en) | 2011-08-25 |
DK2355812T3 (da) | 2019-10-07 |
US9446013B2 (en) | 2016-09-20 |
EP2355812A4 (en) | 2012-04-18 |
EP2355812A2 (en) | 2011-08-17 |
CN102202661A (zh) | 2011-09-28 |
CA2743434A1 (en) | 2010-05-20 |
JP2015091855A (ja) | 2015-05-14 |
AU2009315314B2 (en) | 2013-04-18 |
EP2355812B1 (en) | 2019-07-10 |
BRPI0915247A2 (pt) | 2016-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Xiao et al. | Biological activities of egg yolk lipids: A review | |
Botham et al. | Postprandial lipoproteins and the molecular regulation of vascular homeostasis | |
Harris et al. | Stearidonic acid-enriched soybean oil increased the omega-3 index, an emerging cardiovascular risk marker | |
Braeckman et al. | Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on plasma and red blood cell fatty acids in patients with very high triglyceride levels (results from the MARINE study) | |
JP2015091855A (ja) | アテローム性動脈硬化症の治療のための循環酸化低密度リポタンパク質‐ベータ‐2‐糖タンパク質1複合体を減少させる方法 | |
Kagan et al. | Acute appearance of fatty acids in human plasma–a comparative study between polar-lipid rich oil from the microalgae Nannochloropsis oculata and krill oil in healthy young males | |
KR101383006B1 (ko) | 고중성지방혈증 치료 방법 | |
CA2599112C (en) | Composition comprising dihomo-.gamma.-linolenic acid (dgla) as the active ingredient | |
Dahlin et al. | Plasma phospholipid fatty acids are influenced by a ketogenic diet enriched with n-3 fatty acids in children with epilepsy | |
Fares et al. | Omega-3 fatty acids: a growing ocean of choices | |
Juturu | Omega‐3 fatty acids and the cardiometabolic syndrome | |
JP2006517222A (ja) | コレステロール及びトリグリセリドの減少で使用するための、ジアシルグリセロール及びフィトステロールエステルを富化させた油 | |
Samson et al. | Fatty acid composition and stoichiometry determine the angiogenesis microenvironment | |
Yoshida et al. | Beneficial effect of gemfibrozil on the chemical composition and oxidative susceptibility of low density lipoprotein: a randomized, double-blind, placebo-controlled study | |
Ling et al. | Early development of essential fatty acid deficiency in rats: fat-free vs. hydrogenated coconut oil diet | |
Chen et al. | Extract of Zanthoxylum bungeanum maxim seed oil reduces hyperlipidemia in hamsters fed high-fat diet via activation of peroxisome proliferator-activated receptor γ | |
JP7467819B2 (ja) | 炎症性疾患およびアレルギー性疾患の治療、予防または改善剤 | |
Sherratt | Elucidating Mechanisms of Action of Eicosapentaenoic Acid in Models of Atherosclerotic Cardiovascular Disease | |
Kaur | Parenteral betaine as a strategy to prevent fatty liver and improve docosahexaenoic acid and arachidonic acid distribution in parenterally fed neonatal piglets | |
Liu | LDL oxidation and LDL particle size in the development of atherosclerosis | |
Hopland | Short term effect of omega-3 products on biomarkers of oxidative stress in healthy volunteers: a randomized controlled trial | |
Choudhury et al. | Exploring the Role of Omega-6/Omega-3 Ratio in Disease Management: Insights from Dietary Impact and Molecular Docking Analyses | |
Katsnelson | Regulation of Skeletal Muscle Glucose and Fat Metabolism by DHA and EPA | |
Koppe et al. | Reduction of arteriosclerotic nanoplaque formation and size by n-3 fatty acids in patients after valvular defect operation | |
Panda et al. | Dietary Lipid Determines the Health of Airway Epithelia and the Lungs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121109 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20121109 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140128 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140428 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20140909 |